Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)
Technology appraisal
Reference number: TA966
Published:
Please note that the company has asked NICE to delay this appraisal. The appraisal will therefore be rescheduled and an update on the revised timelines will be provided when further information is available.